Duloxetine-bupropion combination for treatment-resistant atypical depression: A double-blind, randomized, placebo-controlled trial

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1269-1278

  Fornaro, Michele ^a   Martino, Matteo ^b   Mattei, Chiara ^b   Prestia, Davide ^b   Vinciguerra, Valentina ^b   De Berardis, Domenico ^c   De Pasquale, Concetta ^a   Iasevoli, Felice ^d   Mungo, Sergio ^b   Fornaro, Pantaleo ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ASL 4   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Atypical depression; Bupropion; Duloxetine; Placebo controlled; Randomized trial (RCT); Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; DULOXETINE; PLACEBO; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ADULT; AGED; ANXIETY; ARTICLE; ATYPICAL DEPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; LIKERT SCALE; MALE; MEDICATION COMPLIANCE; MELANCHOLIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESISTANT ATYPICAL DEPRESSION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE; ADOLESCENT; DEPRESSION; DRUG COMBINATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BUPROPION; DEPRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; THIOPHENES; YOUNG ADULT;

EID: 84905019077     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.04.004     Document Type: Article

References (50)

1. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 1999, 4:182-188.
2. APA, 1994. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, in: Association, A.P. (Ed.), Washington, D.C.
3. Asnis G.M., McGinn L.K., Sanderson W.C. Atypical depression: clinical aspects and noradrenergic function. Am. J. Psychiatry 1995, 152:31-36.
4. Barbui C., Hotopf M., Freemantle N., Boynton J., Churchill R., Eccles M.P., Geddes J.R., Hardy R., Lewis G., Mason J.M. WITHDRAWN: treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst. Rev. 2006, 4:181-186.
5. Bares M., Novak T., Kopecek M., Stopkova P., Cermak J., Kozeny J., Hoschl C. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study. Int. J. Psychiatry Clin. Pract. 2013, 17:35-43.
6. Benazzi F. Is atypical depression a moderate severity depression? A 536-case study. J. Psychiatry Neurosci.: Jpn. 1999, 24:244-247.
7. Berigan T.R. The Many uses of bupropion and bupropion sustained release (SR) in adults. Prim. Care Companion J. Clin. Psychiatry 2002, 4:30-32.
8. DeBattista C. Augmentation and combination strategies for depression. J. Psychopharmacol. 2006, 20:11-18.
9. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003, 53:649-659.
10. Fava M., Rush A.J., Thase M.E., Clayton A., Stahl S.M., Pradko J.F., Johnston J.A. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry 2005, 7:106-113.
11. First M.B., Spitzer R., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
12. Fornaro M., Aguglia E., Dell'Osso L., Perugi G. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opin. Pharmacother. 2011, 12:2817-2831.
13. Fornaro M., Giosue P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin. Pract. Epidemiol. Ment. Health: CP EMH 2010, 6:20-24.
14. *D. J. Clin. Psychopharmacol. 2012, 32:114-119.
15. Goldberg J.F., Burdick K.E., Endick C.J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry 2004, 161:564-566.
16. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36:267-275.
17. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959, 32:50-55.
18. Howland R.H., Wilson M.G., Kornstein S.G., Clayton A.H., Trivedi M.H., Wohlreich M.M., Fava M. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann. Clin. Psychiatry: Off. J. Am. Acad. Clin. Psychiatr. 2008, 20:209-218.
19. ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice 1996.
20. Iovieno N., Papakostas G.I. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?. J. Clin. Psychiatry 2012, 73:676-683.
21. Martino M., Rocchi G., Escelsior A., Fornaro M. Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr. Neuropharmacol. 2012, 10:97-123.
22. McGahuey C.A., Gelenberg A.J., Laukes C.A., Moreno F.A., Delgado P.L., McKnight K.M., Manber R. The arizona sexual experience scale (ASEX): reliability and validity. J. Sex Marital Ther. 2000, 26:25-40.
23. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry: J. Ment. Sci. 1979, 134:382-389.
24. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
25. Nierenberg A.A., Alpert J.E., Pava J., Rosenbaum J.F., Fava M. Course and treatment of atypical depression. Journal Clin. Psychiatry 1998, 59(18):5-9.
26. *D. J. Clin. Psychiatry 2005, 66:1002-1011.
27. Nutt D.J., Baldwin D.S., Clayton A.H., Elgie R., Lecrubier Y., Montejo A.L., Papakostas G.I., Souery D., Trivedi M.H., Tylee A. Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 2006, 67(6):46-49.
28. Papakostas G.I. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J. Clin. Psychiatry 2009, 70(6):16-25.
29. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry 2007, 62:1217-1227.
30. Papakostas G.I., Worthington J.J., Iosifescu D.V., Kinrys G., Burns A.M., Fisher L.B., Homberger C.H., Mischoulon D., Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress. Anxiety 2006, 23:178-181.
31. Perugi G., Fornaro M., Akiskal H.S. Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis?. World Psychiatry: Off. J. World Psychiatr. Assoc. 2011, 10:45-51.
32. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., Warden D., Morris D.W., Luther J.F., Husain M.M., Cook I.A., Shelton R.C., Lesser I.M., Kornstein S.G., Wisniewski S.R. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 2011, 168:689-701.
33. Santen G., Horrigan J., Danhof M., Della Pasqua O. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin. Pharmacol. Ther. 2009, 86:255-262.
34. Schultz P. Are all antidepressants alike?. Dialogues Clin. Neurosci. 1999, 1:4-11.
35. Shelton R.C., Andorn A.C., Mallinckrodt C.H., Wohlreich M.M., Raskin J., Watkin J.G., Detke M.J. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int. Clin. Psychopharmacol. 2007, 22:348-355.
36. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., Mendlewicz J Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 1999, 9:83-91.
37. Souery D., Serretti A., Calati R., Oswald P., Massat I., Konstantinidis A., Linotte S., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Zohar J., Mendlewicz J. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J. Clin. Psychopharmacol. 2011, 31:512-516.
38. Spina E., Trifiro G., Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012, 26:39-67.
39. Stewart J.W., Deliyannides D.A., McGrath P.J. Is duloxetine effective treatment for depression with atypical features?. Int. Clin. Psychopharmacol. 2008, 23:333-336.
40. Stewart J.W., McGrath P.J., Fava M., Wisniewski S.R., Zisook S., Cook I., Nierenberg A.A., Trivedi M.H., Balasubramani G.K., Warden D., Lesser I., John Rush A. Do atypical features affect outcome in depressed outpatients treated with citalopram?. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. 2010, 13:15-30.
41. Stewart J.W., McGrath P.J., Quitkin F.M., Klein D.F. DSM-IV depression with atypical features: is it valid?. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34:2625-2632.
42. Stewart J.W., McGrath P.J., Rabkin J.G., Quitkin F.M. Atypical depression. A valid clinical entity?. Psychiatr. Clin. N. Am. 1993, 16:479-495.
43. Thase M.E. Atypical depression: useful concept, but it's time to revise the DSM-IV criteria. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 2009, 34:2633-2641.
44. Trivedi M.H., Corey-Lisle P.K., Guo Z., Lennox R.D., Pikalov A., Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int. Clin. Psychopharmacol. 2009, 24:133-138.
45. *D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
46. West E.D., Dally P.J. Effects of iproniazid in depressive syndromes. Br. Med. J. 1959, 1:1491-1494.
47. Williams J.B.W., Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale With Atypical Depression Supplement (SIGH-ADS) 2003, N.Y.S.P. Institute, New York.
48. WMA, 2008. Declaration of Helsinki: ethical priciples for medical research involving human subjects, in: Association, W.M. (Ed.).
49. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry: J. Ment. Sci. 1978, 133:429-435.
50. Zwarenstein M., Treweek S., Gagnier J.J., Altman D.G., Tunis S., Haynes B., Oxman A.D., Moher D., group C., Pragmatic Trials in Healthcare, g. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Br.Med. J. 2008, 337:a2390.